In the BioHarmony Drug Report Database
Ivabradine
Corlanor, Corlentor, Ivabradine Anpharm, Procoralan (ivabradine) is a small molecule pharmaceutical. Ivabradine was first approved as Corlanor on 2005-10-25. It is used to treat heart failure in the USA. It has been approved in Europe to treat angina pectoris and heart failure. It is known to target potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2, potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1, potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, and potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3. Corlanor’s patent is valid until 2026-02-22 (FDA).
Trade Name
|
Corlentor, Ivabradine Anpharm, Procoralan |
|---|---|
Common Name
|
ivabradine |
ChEMBL ID
|
CHEMBL471737 |
Indication
|
angina pectoris, heart failure |
Drug Class
|
Image (chem structure or protein)